Skip to main content
. 2014 Dec 10;6(2):995–1007. doi: 10.18632/oncotarget.2739

Figure 2. Inhibition of TAK1 attenuates CCR7 expression.

Figure 2

(A) Expression of phospho-TAK1 and TAK1 in MCF-7 and MDA-MB-231 (231) breast cancer cells. (B) Expression of CCR7 mRNA and cell surface CCR7 protein in MCF-7 and MDA-MB-231 (231) cells. (C) MDA-MB-231 cells were treated with different doses of TAK1 inhibitor 5Z-O for 24 h. TAK1 activity was examined by detecting p-TAK1 by immunoblotting. β-actin was used as an internal control. (D) MDA-MB-231 cells were treated with different doses of TAK1 inhibitor 5Z-O for 24 h. CCR7 mRNA was detected by RT-PCR and the cell surface CCR7 protein was studied by flow cytometry.